focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRuffer Regulatory News (RICA)

Share Price Information for Ruffer (RICA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 274.00
Bid: 273.00
Ask: 273.50
Change: 0.50 (0.18%)
Spread: 0.50 (0.183%)
Open: 273.50
High: 274.50
Low: 272.50
Prev. Close: 273.50
RICA Live PriceLast checked at -
Ruffer Investment Company is an Investment Trust

To achieve capital and income return of twice the Bank of England base rate by investing through internationally listed securities and bonds.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monthly Investment Report November 2020

8 Dec 2020 14:05

RNS Number : 9466H
Ruffer Investment Company Limited
08 December 2020
 

RUFFER INVESTMENT COMPANY LIMITED

(a closed-ended investment company incorporated in Guernsey with registration number 41996)

LEI 21380068AHZKY7MKNO47

 

 

Attached is a link to the Monthly Investment Report for November 2020.

 

 

http://www.rns-pdf.londonstockexchange.com/rns/9466H_1-2020-12-8.pdf

 

 

 

During November, the net asset value of the Company rose by 5.2%. This compares with an increase of 12.7% in the FTSE All-Share index.

 

The arrival of Pfizer's efficacy figures for its vaccine on 9 November saw what Jon Dye, our Head of Research, memorably referred to as an "up-crash" in markets and indeed it was one of the most extraordinary days in stock index history. The momentum factor, a popular algorithmic trading strategy that buys the best-performing stocks, whilst going short of the worst-performing stocks, fell by 24% - an eight standard deviation event. Over the month as a whole, the MSCI World equity index (like many others) saw its strongest return (+12.2%) since 1987; for the storied Dow Jones index in the US it was the fourth best month since the Great Depression era (+11.8%).

 

The Company's average equity position performed similarly strongly rising over 15%, reflecting our ongoing tilt towards recovery-sensitive value stocks. Our equities overall contributed 5.9% to the monthly performance. On the other side of the ledger were those protective assets that performed so strongly in the down-crash of March: options (-0.3%) and gold (-0.5%). The damage here has been limited by profit-taking in recent months.

 

Conspicuous by its absence from these statistics is the bond market. Bond yields hardly reacted in November. Their progress from here is of enormous importance for asset prices. Equity markets are racing to assert that the vaccine allows the investor a line of sight to strong economic growth in 2021. If bond markets come to share this view, then yields could rise steeply. This would undermine the central foundation of high asset prices. Gold, growth stocks and credit would all suffer. Few assets would benefit with value stocks, especially energy and financial stocks being the exception. These are well represented in the portfolio. If, instead, the US Federal Reserve succeeds in capping bond yields, while taking a relaxed stance on rising inflation, then initially all asset classes may benefit, with the notable exception of the US dollar. Commodities and inflation-linked bonds will likely be at the forefront.

 

So where now for markets and the Company? Conscious of the economic reality on the ground, the portfolio is protected against a deflationary default cycle with the credit protection strategies that performed so well in March. Our greater conviction, however, is that governments will continue to rely on the now trusted 'More Money Today' strategy of fiscal and monetary stimulus, making today's lockdowns yesterday's concern. The vaccines allow equity markets to see a bridge to a brighter world, just over the horizon. If this is right, then value stocks will have their day in the sun, before the hangover of dealing with the financial cost of the pandemic is truly addressed through financial repression. Our equity exposure is designed to benefit from this interlude and the index-linked bonds are there for the aftermath

 

 

Enquiries:

 

Praxis Fund Services Limited

Gail Adams

DDI: +44(0)1481 755584

Email: ric@praxisifm.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCTPBTTMTJMBBM
Date   Source Headline
29th Feb 20247:01 amRNSDividend Declaration
29th Feb 20247:00 amRNSHalf-year Report
28th Feb 202412:11 pmRNSNet Asset Value(s)
28th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20248:09 amRNSTransaction in Own Shares
21st Feb 202410:52 amRNSNet Asset Value(s)
16th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 202411:46 amRNSNet Asset Value(s)
13th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares - replacement
8th Feb 20247:00 amRNSMonthly Investment Report - January 2024
7th Feb 20241:05 pmRNSNet Asset Value(s)
7th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 20247:00 amRNSTransaction in Own Shares
2nd Feb 20247:00 amRNSTransaction in Own Shares
1st Feb 202411:30 amRNSNet Asset Value(s)
31st Jan 20242:55 pmRNSTotal Voting Rights
31st Jan 20241:36 pmRNSNet Asset Value(s)
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSTransaction in Own Shares
29th Jan 20247:00 amRNSTransaction in Own Shares
26th Jan 20247:00 amRNSTransaction in Own Shares
25th Jan 20247:00 amRNSTransaction in Own Shares
24th Jan 202412:57 pmRNSNet Asset Value(s)
23rd Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 20247:00 amRNSTransaction in Own Shares
17th Jan 202412:22 pmRNSNet Asset Value(s)
17th Jan 20247:00 amRNSInvestment Manager's Period End Review
12th Jan 20247:00 amRNSMonthly Investment Report - December 2023
10th Jan 202411:22 amRNSNet Asset Value(s)
8th Jan 20247:00 amRNSTransaction in Own Shares
3rd Jan 202412:50 pmRNSNet Asset Value(s)
3rd Jan 202410:09 amRNSNet Asset Value(s)
27th Dec 20232:50 pmRNSNet Asset Value(s)
20th Dec 20231:49 pmRNSNet Asset Value(s)
13th Dec 20234:15 pmRNSNet Asset Value(s)
13th Dec 20237:00 amRNSMonthly Investment Report - November 2023
6th Dec 20235:00 pmRNSNet Asset Value(s)
1st Dec 202310:42 amRNSNet Asset Value(s)
30th Nov 20234:33 pmRNSResult of AGM
29th Nov 20233:30 pmRNSNet Asset Value(s)
22nd Nov 202312:13 pmRNSNet Asset Value(s)
15th Nov 20232:59 pmRNSNet Asset Value(s)
14th Nov 20237:00 amRNSMonthly Investment Report - October 2023
8th Nov 20232:03 pmRNSNet Asset Value(s)
1st Nov 20231:17 pmRNSNet Asset Value(s)
27th Oct 20234:00 pmRNSNotice of AGM
25th Oct 20231:33 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.